Roxbury Financial LLC Boosts Stake in Amgen Inc. $AMGN

Roxbury Financial LLC increased its position in Amgen Inc. (NASDAQ:AMGN) by 9.6% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,154 shares of the medical research company’s stock after purchasing an additional 188 shares during the quarter. Roxbury Financial LLC’s holdings in Amgen were worth $602,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in AMGN. Brighton Jones LLC grew its position in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares during the period. Forum Financial Management LP grew its holdings in Amgen by 0.7% in the fourth quarter. Forum Financial Management LP now owns 352,784 shares of the medical research company’s stock worth $91,950,000 after purchasing an additional 2,411 shares during the period. Scientech Research LLC increased its stake in shares of Amgen by 16.0% during the fourth quarter. Scientech Research LLC now owns 4,279 shares of the medical research company’s stock valued at $1,115,000 after purchasing an additional 591 shares in the last quarter. Safe Harbor Fiduciary LLC bought a new position in shares of Amgen during the fourth quarter valued at approximately $130,000. Finally, Studio Investment Management LLC lifted its holdings in shares of Amgen by 0.9% during the fourth quarter. Studio Investment Management LLC now owns 12,390 shares of the medical research company’s stock valued at $3,229,000 after purchasing an additional 114 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several recent research reports. Morgan Stanley upped their price target on Amgen from $330.00 to $333.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Guggenheim assumed coverage on Amgen in a research note on Tuesday, May 20th. They issued a “neutral” rating and a $288.00 target price on the stock. Bank of America lifted their price target on Amgen from $252.00 to $261.00 and gave the stock an “underperform” rating in a research report on Wednesday, July 23rd. UBS Group cut their price objective on shares of Amgen from $326.00 to $317.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 6th. Finally, William Blair restated an “outperform” rating on shares of Amgen in a research note on Tuesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Amgen has an average rating of “Hold” and a consensus price target of $304.43.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $276.39 on Friday. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The firm has a market cap of $148.80 billion, a price-to-earnings ratio of 22.60, a price-to-earnings-growth ratio of 2.46 and a beta of 0.49. The business has a 50-day simple moving average of $292.54 and a two-hundred day simple moving average of $291.66. Amgen Inc. has a fifty-two week low of $253.30 and a fifty-two week high of $339.17.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 EPS for the quarter, topping analysts’ consensus estimates of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm had revenue of $9.18 billion during the quarter, compared to analyst estimates of $8.86 billion. During the same period in the previous year, the business posted $4.97 earnings per share. The business’s revenue for the quarter was up 9.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. On average, analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 12th. Shareholders of record on Friday, August 22nd were paid a dividend of $2.38 per share. The ex-dividend date was Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a yield of 3.4%. Amgen’s payout ratio is currently 77.84%.

Insider Activity

In related news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total value of $376,286.33. Following the completion of the sale, the senior vice president owned 7,209 shares of the company’s stock, valued at $2,141,000.91. The trade was a 14.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.76% of the stock is currently owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.